Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid appoints experienced retail executive to board as it targets US and Asia

Dennis Eck has also been engaged in developing the retail strategies of US groups as well as Coles Myer.
Picture of woman with evolis caption
Eck should provide valuable input regarding product and distribution strategies for évolis

Cellmid Limited (ASX:CDY) has appointed Dennis Eck to the board as non-executive director.

A professional investor, Eck has 40 years’ senior management experience in the retail sector, leading the strategic direction of companies such as American Stores, Vons and ULTA in the US.

He has also been engaged in a similar capacity with Coles Myer in Australia.

Relevant experience in cosmetics and hair care

Eck’s retail experience spans from fashion through to groceries and includes cosmetics and hair salons.

As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses, delivering outstanding shareholder returns.

Cellmid chairman David King said: “We are delighted to welcome Dennis to the board and look forward to his continued valuable input regarding our product and distribution strategy for évolis.”

Important in entering US and Asian markets

With substantial US and Asian market opportunities for évolis®, Eck’s experience should be beneficial.

In December 2017, Eck made a strategic investment in Cellmid through a private placement by acquiring 2.7 million fully paid ordinary shares.

Consequently, his interests are closely aligned with the shareholders he represents. 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use